Xylem Appoints Andrea van der Berg As Executive VP And CFO Effective September 1, Succeeding William “Bill” Grogan

Xylem (XYL) Down 7.1% Since Last Earnings Report: Can It Rebound?

Xylem reported Q2 2026 adjusted earnings of $1.46 per share, beating consensus estimates by 9%, with revenues of $2.34 billion slightly exceeding expectations. The company raised its 2026 guidance with adjusted earnings now forecast at $5.55-$5.70 per share and EBITDA margin expansion of 90-130 basis points. However, shares have underperformed the S&P 500 by 7.1% since the earnings report, and analyst estimates have trended downward in the past month, resulting in a Zacks Rank #3 (Hold) rating.

Xylem shares are trading lower after the company announced an executive transition and affirmed its Q3 and FY26 sales guidance below analyst estimates.

Xylem Affirms FY2026 Adj EPS Guidance of $5.55-$5.70 vs $5.54 Est; Affirms FY2026 Sales Guidance of $9.200B vs $9.254B Est

Xylem (NYSE:XYL) affirms FY2026 Adj EPS guidance from $5.55-$5.70 to $5.55-$5.70 vs $5.54 analyst estimate. Affirms FY2026 sales outlook from $9.200 billion to $9.200 billion vs $9.254 billion estimate.

Xylem Affirms Q3 Adj EPS Guidance of $1.42-$1.47 vs $1.46 Est; Affirms Q3 Sales Guidance of $2.300B vs $2.316B Est

Xylem (NYSE:XYL) affirms Q3 Adj EPS guidance from $1.42-$1.47 to $1.42-$1.47 vs $1.46 analyst estimate. Affirms Q3 sales outlook from $2.300 billion to $2.300 billion vs $2.316 billion estimate.